The Rx|X Blog Madeline Wallack 3/17/25 Madeline Wallack 3/17/25 340B Economics 101 Read More Madeline Wallack 2/28/25 Madeline Wallack 2/28/25 The 340B Rebate Model: A Fundamental Disruption Without Clear Benefit to Patients Read More Madeline Wallack 2/19/25 Madeline Wallack 2/19/25 340B Operations Experience: A Key Consideration Missing from the Debate Read More Madeline Wallack 1/18/25 Madeline Wallack 1/18/25 Quick Q&A with Rx|X Founders Read More Madeline Wallack 11/25/24 Madeline Wallack 11/25/24 Three Actions Entities Can Take to Improve the HRSA Audit Process. Read More Madeline Wallack 11/6/24 Madeline Wallack 11/6/24 HRSA 340B Audits: Quantity vs. Quality in the Audit Process Read More Madeline Wallack 11/4/24 Madeline Wallack 11/4/24 AstraZeneca’s New 340B Replenishment Policy: An Unexpected Yet Welcome Change Read More
Madeline Wallack 2/28/25 Madeline Wallack 2/28/25 The 340B Rebate Model: A Fundamental Disruption Without Clear Benefit to Patients Read More
Madeline Wallack 2/19/25 Madeline Wallack 2/19/25 340B Operations Experience: A Key Consideration Missing from the Debate Read More
Madeline Wallack 11/25/24 Madeline Wallack 11/25/24 Three Actions Entities Can Take to Improve the HRSA Audit Process. Read More
Madeline Wallack 11/6/24 Madeline Wallack 11/6/24 HRSA 340B Audits: Quantity vs. Quality in the Audit Process Read More
Madeline Wallack 11/4/24 Madeline Wallack 11/4/24 AstraZeneca’s New 340B Replenishment Policy: An Unexpected Yet Welcome Change Read More
